GRAIL published validation data for the company’s multi-cancer early detection blood test, which can detect more than 50 different cancer types across all stages.
U.S. regulators approved AstraZeneca’s Imfinzi treatment for use against an aggressive type of lung cancer in previously untreated patients.
Researchers with the Abramson Cancer Center of the University of Pennsylvania, led by Carl June, published results from the first U.S. Phase I trial of CRISPR-Cas9-edited T-cells in humans with advanced cancer.
Researchers from the Abramson Cancer Center of the University of Pennsylvania described a death receptor pathway in cancer cells that has a primary role in its response to CAR-T cells.
Researchers at Cardiff University in the UK have essentially identified a new T-cell and its receptor that can search out and kill a broad range of cancer cells.
Scientists at the Broad Institute of MIT and Harvard tested about 4,518 drugs on 578 human cancer cell lines, and discovered that almost 50 had previously unrecognized anti-cancer properties.
Cellectis announced a paper published in Nature Communications that describes a proof-of-concept for rewiring the cell pathway to create highly intelligent T-cells that can recognize cancerous tumors and cause a micro secretion of therapeutic proteins onto these tumors, which ultimately reshapes the tumor microenvironment and improves the T-cells ability to fight cancer.
For Breast Cancer Awareness Month, BioSpace gathered examples of recent breakthroughs in breast cancer treatment.
Yale University researchers developed a new system dubbed Multiplexed Activation of Endogenous Genes as Immunotherapy (MAEGI) that hunts down cancer cells.
Less than a month after the company’s Phase III brain cancer treatment failed, San Diego-based Tocagen is undergoing a restructuring and will reduce the employee workforce by 65 percent.
